Literature DB >> 23728821

Perceptions of under and overutilization of cervical cancer screening services at Latino-serving community health centers.

Gloria D Coronado1, Amanda Petrik, Mark Spofford, Jocelyn Talbot, Huyen Hoai Do, Jennifer Sanchez, Tanya Kapka, Vicky Taylor.   

Abstract

We sought to gather the perceptions of clinic personnel at Latino-serving Federally Qualified Health Centers (FQHCs) about patients' utilization of screening services for cervical cancer. We conducted one-on-one interviews among 17 clinic personnel at four Latino-serving FQHCs in Oregon. The clinic personnel we interviewed observed both under and overutilization of cervical cancer screening services. Clinic personnel estimated that 20-60 % of eligible patients were underscreened for cervical cancer, with 30 % the most commonly cited percentage. Underscreening was thought to occur among low-income, underinsured, and undocumented patients. Overscreening for cervical cancer was estimated to occur in 10-50 % of eligible patients, with 10 % the most frequently cited proportion. Overscreening was thought to occur among women younger than age 21 and women with a recent pregnancy. Our findings may inform future efforts to promote guideline-appropriate cancer screening and coordinated follow-up care.

Entities:  

Mesh:

Year:  2013        PMID: 23728821     DOI: 10.1007/s10900-013-9701-1

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  6 in total

Review 1.  Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness.

Authors:  U H Graneheim; B Lundman
Journal:  Nurse Educ Today       Date:  2004-02       Impact factor: 3.442

2.  Cancer screening - United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-01-27       Impact factor: 17.586

Review 3.  Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis.

Authors:  M Kyrgiou; G Koliopoulos; P Martin-Hirsch; M Arbyn; W Prendiville; E Paraskevaidis
Journal:  Lancet       Date:  2006-02-11       Impact factor: 79.321

4.  The qualitative content analysis process.

Authors:  Satu Elo; Helvi Kyngäs
Journal:  J Adv Nurs       Date:  2008-04       Impact factor: 3.187

5.  Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?

Authors:  Mona Saraiya; Zahava Berkowitz; K Robin Yabroff; Louise Wideroff; Sarah Kobrin; Vicki Benard
Journal:  Arch Intern Med       Date:  2010-06-14

6.  Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS).

Authors:  Isam A Eltoum; Janie Roberson
Journal:  Cancer       Date:  2007-02-25       Impact factor: 6.860

  6 in total
  4 in total

1.  Correlates of Cervical Cancer Screening Adherence Among Women in the U.S.: Findings from HINTS 2013-2014.

Authors:  John S Luque; Yelena N Tarasenko; Chen Chen
Journal:  J Prim Prev       Date:  2018-08

2.  Primary care providers human papillomavirus vaccine recommendations for the medically underserved: a pilot study in U.S. Federally Qualified Health Centers.

Authors:  Katherine B Roland; Vicki B Benard; April Greek; Nikki A Hawkins; Mona Saraiya
Journal:  Vaccine       Date:  2014-08-12       Impact factor: 3.641

3.  Comparative effectiveness of two outreach strategies for cervical cancer screening.

Authors:  Erin J Aiello Bowles; Hongyuan Gao; Susan Brandzel; Susan Carol Bradford; Diana S M Buist
Journal:  Prev Med       Date:  2016-01-25       Impact factor: 4.018

4.  Who are the under- and never-screened for cancer in Ontario: a qualitative investigation.

Authors:  Dionne Gesink; Alanna Mihic; Joan Antal; Brooke Filsinger; C Sarai Racey; Daniel Felipe Perez; Todd Norwood; Farah Ahmad; Nancy Kreiger; Paul Ritvo
Journal:  BMC Public Health       Date:  2014-05-23       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.